21493 - PH3 Place Capi+ Doce Place+ Doce mCRPC

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)

Disease Types: Prostate,&nbs

Available at: {clinical_trial_location backspace="7"} 21493 - PH3 Place Capi+ Doce Place+ Doce mCRPC, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}